A Clinical Feature of Hyperlipidemia in Patients with Central Diabetes Insipidus.

Abstract

Abstract.In this study, we analyzed plasma lipid and lipoprotein levels before and after treatment with 1-desamino-8-D-arginine vasopressin (DDAVP) in subjects with partial and complete central diabetes Insipidus (DI) in order to determine how a shortage and supplement of this hormone affect plasma lipid metabolism.The subjects consisted of 6 patients with partial and 6 with complete central DI. After treatment with DDAVP through nasal cavity, plasma total cholesterol (TC) level did not decrease either in complete or partial form. Plasma triglyceride (TG) levels decreased from 306± 175 mg/dl to 198±91(35% decrease, p=0.027) in complete form, while TG did not change significantly in partial form. A detailed investigation of plasma lipoprotein metabolism during treatment with DDAVP was carried out in 3 of the 6 subjects with complete form of DI. Lipoprotein lipase activity and mass in post-heparin plasma from those three subjects tended to increase after treatment with DDAVP, along with the complete disappearance of an unusual lipoprotein between low density lipoprotein (LDL) and very low density lipoprotein (VLDL) as analyzed by polyacrylamide gel electrophoresis.These results suggest that the DDAVP treatment has a favorable effect on lipid and lipoprotein metabolism, especially triglyceride-rich lipoproteins, either directly or through modifying factors contributing to lipid metabolism.

Elevated High-Density Lipoprotein Cholesterol Is Associated with Hyponatremia in Hypertensive Patients

“…32,33 Finally, when AVP stimulation is absent, as in individuals who suffer from complete central diabetes insipidus and lack endogenic AVP, there is dyslipidemia. 34 In these patients, treatment with desamino-D-arginine vasopressin (DDAVP) improves the lipid profile and increases HDL-C levels.…”

Rethinking Vasopressin: New Insights into Vasopressin Signaling and Its Implications

“…In healthy patients, treatment with a V1aR agonist (lysine-vasopressin) led to a decrease of nonesterified fatty acids in plasma. 44 In addition, patients with central diabetes insipidus treated with a V2R agonist (desmopressin) led to an increase in lipoprotein lipase activity and a decrease in both LDL and VLDL 45 while the use of a V2R antagonist (tolvaptan) in patients with polycystic kidney disease has been reported to increase LDL and total cholesterol. 46 Together, the association and experimental data in humans strongly suggest that vasopressin is involved in regulating both glucose and lipid metabolism.…”